Neurocrine Biosciences, Inc. (NBIX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 145.8M | 388.4M | 227.5M | 102M | 64.8M | 242.5M | 158M | 64.6M | 130.3M | 123.5M | 212M | 179.6M |
| Operating CF Margin % | 17.9% | 48.22% | 28.62% | 14.84% | 11.32% | 38.63% | 25.4% | 10.95% | 25.29% | 23.97% | 42.5% | 39.67% |
| Operating CF Growth % | 125% | 60.16% | 43.99% | 57.89% | -50.27% | 96.36% | -25.47% | -64.03% | 204.07% | -13.64% | 114.57% | 30.05% |
| Net Income | 197.9M | 153.7M | 209.5M | 107.5M | 7.9M | 103.1M | 129.8M | 65M | 43.4M | 147.7M | 83.1M | 95.5M |
| Depreciation & Amortization | 7.3M | 7.5M | 7.7M | 7.3M | 7.6M | 7.1M | 6.5M | 7.3M | 6.2M | 5.7M | 5.5M | 5.1M |
| Stock-Based Compensation | 57.2M | 58.6M | 53.7M | 52.8M | 52.8M | 66.4M | 41.5M | 43.1M | 44.5M | 38.1M | 47.8M | 68.5M |
| Deferred Taxes | -61.1M | 48.2M | 168.3M | -37.4M | -13.7M | -31.3M | -34.9M | -41.3M | -15.6M | 20.6M | -4.2M | -41.5M |
| Other Non-Cash Items | -55.5M | 1.2M | -274.5M | 10.9M | 33.9M | 2.9M | 10.7M | 76.8M | 83.4M | -34.9M | 33.8M | -41.4M |
| Working Capital Changes | 0 | 119.2M | 62.8M | -39.1M | -23.7M | 94.3M | 4.4M | -86.3M | -31.6M | -53.7M | 46M | 93.4M |
| Change in Receivables | -81.4M | 38.4M | -132.3M | -79.7M | -36.9M | 2M | -12.9M | -17.6M | -11.3M | -21.4M | -30.4M | 4.2M |
| Change in Inventory | 4.3M | -3.4M | -12.3M | 2.1M | -1.7M | -11.6M | -3.3M | -5.3M | 1.1M | -900K | 2.9M | 1.6M |
| Change in Payables | -14.3M | 76.5M | 55.8M | 15.5M | 12.4M | 67.7M | 39.4M | -59.5M | -18.6M | -83M | 124.4M | 16.2M |
| Cash from Investing | -506.2M | -52.9M | -196.7M | -29M | 14.2M | -68.3M | 24.7M | -28.2M | -55M | -201.8M | -97.3M | -125.9M |
| Capital Expenditures | -9.1M | 2.4M | -13.2M | -12.5M | -10.7M | -7.3M | -8.1M | -11.6M | -11.2M | -5.4M | -7.6M | -6.8M |
| CapEx % of Revenue | 1.12% | 0.3% | 1.66% | 1.82% | 1.87% | 1.16% | 1.3% | 1.97% | 2.17% | 1.05% | 1.52% | 1.5% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 63.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -86.1M | 37.3M | 45.6M | -3.3M | -117.9M | -290M | 26.4M | -293M | 69.9M | 35.4M | 18.8M | 2.9M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 37.3M | 45.6M | -3.3M | -117.9M | -290M | 26.4M | 15.8M | 69.9M | 35.4M | 18.8M | 2.9M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -54M | 0 | 0 | -17.7M | -150M | -300M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -86.1M | 0 | 0 | 0 | 0 | 0 | 0 | -308.8M | 0 | 0 | 0 | 0 |
| Net Change in Cash | -446.5M | 372.8M | 76.2M | 69.9M | -38.9M | -116.1M | 209.4M | -256.6M | 145.2M | -42.6M | 133.5M | 56.6M |
| Free Cash Flow | 136.7M | 390.8M | 214.3M | 89.5M | 54.1M | 235.2M | 149.9M | 53M | 119.1M | 118.1M | 204.4M | 172.8M |
| FCF Margin % | 16.78% | 48.52% | 26.96% | 13.02% | 9.45% | 37.47% | 24.1% | 8.98% | 23.11% | 22.92% | 40.98% | 38.17% |
| FCF Growth % | 152.68% | 66.16% | 42.96% | 68.87% | -54.58% | 99.15% | -26.66% | -69.33% | 189.08% | -16.36% | 103.38% | 33.64% |
| FCF per Share | 1.32 | 3.81 | 2.09 | 0.89 | 0.53 | 2.29 | 1.44 | 0.51 | 1.15 | 1.15 | 2.02 | 1.72 |
| FCF Conversion (FCF/Net Income) | 0.74x | 2.53x | 1.09x | 0.95x | 8.20x | 2.35x | 1.22x | 0.99x | 3.00x | 0.84x | 2.55x | 1.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 2.7M | -1.6M | 0 | 1.6M | 0 | 1.9M | 0 | 1.9M |
| Taxes Paid | 0 | 7.8M | 1.1M | 71.9M | 600K | -144.5M | 51.7M | 92.6M | 200K | 46.5M | 1.6M | 3.2M |